The Garvan Institute of Medical Research

01 Apr 1999

• By Mark Ratner

The Garvan Institute of Medical Research became an autonomous research institute in 1984. Sponsored research accounts for one-quarter of Garvan's $14 million 1998 operating income. Going forward, it expects its income to derive approximately one-third from grants, one-third from donations, and one third from commercial activities. The bulk of current revenues from commercial activities come from Eli Lilly, Bristol-Myers, and Merck & Co.

The Garvan Institute of Medical Research in Sydney was founded in 1963, at which time it functioned as St. Vincent's Hospital's endocrine research department. The Garvan became an autonomous research institute in 1984 and maintains formal affiliations with St. Vincent's and the University of New South Wales . Its 210 scientists, of whom 50 are MDs or PhDs, focus on understanding the genetic basis of cancer, osteoporosis, arthritis, and mental illness.

Sponsored research funding and tech transfer fees generated $3.9 million (Australian) for the Institute in 1997 and $3.4 million in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

27 Jun 2025

• By Anju Ghangurde

Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

27 Jun 2025

• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

US Tariff Overhang Weighs on Chinese API Exports

26 Jun 2025

• By Dexter Jie Yan

Chinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war.

Can Japan’s Richest Person Save Cell Therapy’s Future?

26 Jun 2025

• By Lisa Takagi

With financial help from the founder of Uniqlo, Japan’s leading facility for induced pluripotent stem cells is aiming to automate production to slash costs and kick-start R&D in the field.